Clinical meaning
Primary sclerosing cholangitis (PSC) is a chronic, progressive cholestatic liver disease characterized by inflammation and fibrosis of the intrahepatic and extrahepatic bile ducts, leading to multifocal biliary strictures, cholestasis, and ultimately biliary cirrhosis. The pathogenesis involves a complex interplay of autoimmune dysregulation, genetic susceptibility (HLA-B8, HLA-DR3 haplotypes), and the gut-liver axis. PSC is strongly associated with inflammatory bowel disease — 70-80% of PSC patients have ulcerative colitis (UC) — supporting the 'aberrant gut homing' hypothesis: activated lymphocytes primed in the inflamed intestinal mucosa express adhesion molecules (alpha4-beta7 integrin, CCR9) that normally direct them back to the gut, but aberrant expression of the corresponding ligands (MAdCAM-1) on hepatic endothelium allows these gut-activated T-cells to be recruited to the liver, where they initiate periductal inflammation. The histological hallmark is 'onion-skin' periductal fibrosis — concentric rings of collagen deposited around medium and large bile ducts by activated portal myofibroblasts, progressively narrowing the ductal lumen. As bile ducts stricture, bile flow is impeded (cholestasis), causing upstream bile acid accumulation. Retained bile acids are directly cytotoxic to hepatocytes and cholangiocytes: hydrophobic bile acids (deoxycholic acid, lithocholic acid) solubilize cell membrane phospholipids, activate mitochondrial apoptotic pathways, and generate reactive oxygen species. The cholestatic pattern is reflected in laboratory findings: alkaline phosphatase (ALP) is characteristically the most elevated enzyme (often 3-10× upper limit of normal) because ALP is concentrated in the bile duct epithelium (cholangiocytes) and is released into the serum when bile ducts are damaged. GGT elevation parallels ALP and confirms the hepatobiliary origin. MRCP (magnetic resonance cholangiopancreatography) is the diagnostic imaging modality of choice, demonstrating the characteristic 'beading' pattern of the bile ducts — multifocal annular strictures alternating with normal-caliber or mildly dilated segments, producing an appearance resembling a beaded necklace. ERCP is reserved for therapeutic intervention (balloon dilation of dominant strictures, stent placement) and for obtaining brush cytology to screen for cholangiocarcinoma — PSC carries a 10-15% lifetime risk of cholangiocarcinoma, the most feared complication, arising from chronic biliary inflammation driving cholangiocyte proliferation and malignant transformation. CA 19-9 levels >129 U/mL have moderate sensitivity for cholangiocarcinoma in PSC patients but lack specificity (also elevated in bacterial cholangitis and other biliary pathology). Ursodeoxycholic acid (UDCA), a hydrophilic bile acid, is often prescribed to improve liver biochemistry (reduces ALP) by displacing toxic hydrophobic bile acids from the bile acid pool and stimulating choleresis, though it has not been proven to halt disease progression or improve transplant-free survival in large trials. Liver transplantation remains the only definitive treatment for end-stage PSC, with excellent 5-year survival rates (>80%), though PSC recurs in the allograft in approximately 20-25% of cases.